OVERVIEW

Multiple Myeloma: A Pathway to Better Outcomes is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Nov 21, 2018 - Nov 21, 2019.

Accreditation:
CME
NACCME designates this live activity for a maximum of .75 AMA PRA Category 1 Credits.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for .75 AAPA Category 1 credit(s).
PAs should only claim credit commensurate with the extent of their participation.

CNE
This continuing nursing education activity awards .75 contact hour.

CPE
This activity is approved for .75 contact hour (0.075 CEU) of continuing pharmacy education
(UAN JA0006201-0000-18-227-H01-P).

Intended Learners:
This activity is designed for directors of oncology practice programs and cancer centers, oncologists, hematologists, commercial and government payers, pathway development executives, reimbursement specialists, specialty pharmacists, HEOR specialists, and other healthcare professionals interested in learning how to implement, integrate, and measure treatment pathways.

Learning Objectives:
• Identify the clinical and economic impact of suboptimal MM management and the factors that limit current therapies
• Evaluate clinical trial data for novel and emerging therapies, including doublet and triplet combinations, within the management of R/R MM
• Review the pharmacoeconomic profiles of newer R/R MM therapies
• Integrate recent therapeutic advances, resource utilization data, and current guidance into MM clinical pathway development and adoption